Literature DB >> 3887760

Intracavitary chemotherapy for malignant disease confined to body cavities.

M Markman.   

Abstract

The direct administration of cytotoxic chemotherapeutic agents into the peritoneal or pleural cavities to treat malignant disease principally involving these regions is based on modeling studies suggesting a major pharmacokinetic advantage for the exposed cavity compared with the plasma. The safety and clinical efficacy of several agents administered directly into body cavities either singly or in combination have now been shown. Additional studies are needed to define optimal drugs, dosages and treatment schedules for the various tumors confined to body cavities. Whether this form of therapy will prove to be superior to standard systemic drug administration will require controlled clinical trials comparing the two treatment methods.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3887760      PMCID: PMC1306028     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  44 in total

1.  Letter: Loculation as a contraindication to intracavitary 32P-chromic phosphate therapy.

Authors:  M Vider; F H Deland; Y Maruyama
Journal:  J Nucl Med       Date:  1976-02       Impact factor: 10.057

2.  Peritoneal electrolyte absorption: analysis of portal, systemic venous, and lymphatic transport.

Authors:  A R Kraft; R K Tompkins; J E Jesseph
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

3.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

4.  Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer.

Authors:  R F Ozols; R C Young; J L Speyer; P H Sugarbaker; R Greene; J Jenkins; C E Myers
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

5.  Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: a randomized study.

Authors:  R F Kefford; R L Woods; R M Fox; M H Tatterall
Journal:  Med J Aust       Date:  1980-10-18       Impact factor: 7.738

6.  Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.

Authors:  S B Howell; B B Chu; W E Wung; B M Metha; J Mendelsohn
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

7.  The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies.

Authors:  J L Speyer; C E Myers
Journal:  Recent Results Cancer Res       Date:  1980

8.  Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.

Authors:  S B Howell; R Taetle
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

9.  Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.

Authors:  M E King; C E Pfeifle; S B Howell
Journal:  J Clin Oncol       Date:  1984-06       Impact factor: 44.544

10.  Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro.

Authors:  R E Durand
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

View more
  2 in total

1.  Preoperative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications.

Authors:  W Adachi; S Koike; M Rafique; S Kajikawa; G Kaneko; T Kuroda; F Iida; K Ishii
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

2.  [Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].

Authors:  H Rückle; G Ehninger; F Jakob; K Wilms
Journal:  Klin Wochenschr       Date:  1986-05-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.